Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Tango Therapeutics, Inc.
Pliant Therapeutics, Inc.
Cogent Biosciences, Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tango Therapeutics, Inc.
Astellas Pharma Inc
InnoPharmax Inc.
Novartis
Virogin Biotech Ltd.
J-Pharma Co., Ltd.
Taiho Oncology, Inc.
Hutchmed
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
Rigel Pharmaceuticals
Arbele Limited
Alentis Therapeutics AG
Hoffmann-La Roche
Imugene Limited
AstraZeneca
Eisai Inc.
Elevar Therapeutics
Seagen Inc.
Servier
Arvinas Inc.
Myeloid Therapeutics
Servier
New Phase Ltd.
Amgen
DualityBio Inc.
Bold Therapeutics, Inc.
SOFIE
Genfit
Seagen Inc.
TransThera Sciences (Nanjing), Inc.
Apollo Therapeutics Ltd
Taiho Oncology, Inc.
Alaunos Therapeutics
TriSalus Life Sciences, Inc.
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
MacroGenics
Jazz Pharmaceuticals
Elicio Therapeutics
TCR2 Therapeutics